Approximately 20% to 30% of men with prostate cancer experience disease recurrence within 5 years of therapeutic intervention. 1 A key challenge in managing these patients is a scarcity of accurate ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

Assessments used to calculate cardiovascular disease risk in the general population may not have the same predictive power ...

In a recent study published in the journal Nutrients, researchers investigated the associations between urinary bisphenol A (BPA) concentrations (exposure) and the prostate-specific antigen (PSA; ...

Prostate cancer is still associated with fear and social stigma, despite being the second most common cancer among men and one that needs attention. A urologist explained that advances in treatment ...